BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC lifted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 4.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,163,743 shares of the biotechnology company's stock after purchasing an additional 84,102 shares during the period. BioCryst Pharmaceuticals comprises 0.9% of Rice Hall James & Associates LLC's investment portfolio, making the stock its 28th largest holding. Rice Hall James & Associates LLC owned approximately 1.05% of BioCryst Pharmaceuticals worth $16,444,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in BCRX. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock valued at $57,000 after acquiring an additional 1,322 shares in the last quarter. Xponance Inc. increased its position in shares of BioCryst Pharmaceuticals by 13.1% during the 2nd quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 1,505 shares during the last quarter. Creative Planning raised its position in BioCryst Pharmaceuticals by 5.9% in the third quarter. Creative Planning now owns 49,347 shares of the biotechnology company's stock worth $375,000 after acquiring an additional 2,734 shares during the period. CWM LLC lifted its stake in BioCryst Pharmaceuticals by 200.0% in the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 3,772 shares during the last quarter. Finally, Diversified Trust Co grew its stake in shares of BioCryst Pharmaceuticals by 18.0% during the 2nd quarter. Diversified Trust Co now owns 24,752 shares of the biotechnology company's stock worth $153,000 after acquiring an additional 3,774 shares during the period. 85.88% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on BCRX shares. HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. JMP Securities boosted their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a "market outperform" rating in a research report on Tuesday, August 6th. Royal Bank of Canada restated an "outperform" rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. StockNews.com raised shares of BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday, August 6th. Finally, Barclays increased their target price on BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the stock an "equal weight" rating in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $14.17.

BioCryst Pharmaceuticals Price Performance

BCRX stock traded up $0.42 during mid-day trading on Friday, reaching $8.43. The company had a trading volume of 2,877,670 shares, compared to its average volume of 2,935,122. The firm has a 50 day moving average of $7.85 and a 200 day moving average of $6.87. The company has a market capitalization of $1.74 billion, a PE ratio of -11.55 and a beta of 1.88. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.11. The business had revenue of $109.30 million for the quarter, compared to analyst estimates of $98.30 million. During the same period in the previous year, the company posted ($0.24) earnings per share. The business's revenue for the quarter was up 34.9% on a year-over-year basis. Analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.37 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.